2
Registered trials
2
Recruiting
2
Unique sponsors
4
Unique IMPs
2
Commercial trials
Drug classes (ATC)
—
ATC code not specified
2
Mechanism of action (INN-stem analysis)
Unknown / small molecule
2 substances
Kinase inhibitor
1 substance
Monoclonal antibody
1 substance
Phase II:
2
Phase II
2 trials-
RecruitingBayer Consumer Care AG Commercial3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE; BAY 2927088; SEVABERTINIB
-
RecruitingJazz Pharmaceuticals Ireland Limited CommercialZANIDATAMAB
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Bayer Consumer Care AG | Commercial | 1 | Phase II | 1 |
| Jazz Pharmaceuticals Ireland Limited | Commercial | 1 | Phase II | 1 |
New trials by year
2025
1
2026
1